Table of Contents
Table of Contents
Foreword
Rafael Rosell, M.D. (President of the Spanish Lung Cancer Group)
About the Editor
Diego Márquez-Medina, M.D., Ph.D.
Introduction
Chapter 1 – Lung Cancer I. Epidemiology, Pathology and Diagnosis. Tissue Sampling (pp. 1-16)
Amaia Ojanguren, M.D., Ph.D., Miriam Barrecheguren, M.D. and Iñigo Ojanguren, M.D. (Arnau of Vilanova University Hospital of Lleida, Spain and others)
Chapter 2 – Lung Cancer II. Conventional Treatment for Advanced Non-Small Cell Lung Cancer (pp. 17-42)
Oscar Juan-Vidal, M.D. and Corina Escoin, Ph.D. (La Fe University Hospital of Valencia, Spain)
Chapter 3 – Biology I. Human Epidermal Growth Factor Receptors in Health and Tumor Cells (pp. 43-54)
M. Ángeles Montero-Fernández, M.D., Ph.D. (Royal Brompton and Harefield Trust of London, United Kingdom)
Chapter 4 – Biology II. Etiology and Histology of Lung Cancer According to the Presence of Alterations in the Human Epidermal Growth Factor Family of Receptors (pp. 55-70)
Diego Márquez-Medina, M.D., Ph.D. (Arnau de Vilanova University Hospital of Lleida, Spain)
Chapter 5 – Laboratory I. Analysis of Human Epidermal Growth Factor Receptors: Conventional Analysis (pp. 71-90)
Beatriz Bellosillo, Ph.D. and Luz Martínez-Avilés, B.S. (Hospital del Mar University Hospital of Barcelona, Spain)
Chapter 6 – Laboratory II. Experimental Analysis of Human Epidermal Growth Factor Receptors (pp. 91-106)
Javier Hernández-Losa, Ph.D. (Vall d’Ebron University Hospital of Barcelona, Spain)
Chapter 7 – Timing I: Dynamic Analysis of Human Epidermal Growth Factor Receptors. Role of Rebiopsy (pp. 107-114)
Santiago Viteri, M.D. and Alejandro Martínez-Bueno, M.D. (Instituto Rosell de Oncología of Barcelona, Spain)
Chapter 8 – Timing II. Appropriate Time to Determine the Presence of EGFR Mutation and Sequence of Treatment (pp. 115-130)
Teresa Morán, M.D., Enric Carcereny, M.D., María de los Llanos Gil, M.D., Laia Vilà, M.D., Alberto Indacochea and Jordi Remón, M.D. (Catalan Institut of Oncology of Badalona, Spain)
Chapter 9 – Treatment I – Treatment of Unselected Patients with Epidermal Growth Factor Tyrosine Kinase Inhibitors (pp. 131-152)
Edurne Arriola, M.D., Álvaro Taus, M.D. and David Casadevall, M.D. (Hospital del Mar University Hospital of Barcelona, Spain)
Chapter 10 – Treatment II. Treatment of Selected Non-Small Cell Lung Cancer Patients (pp. 153-162)
Ramon Palmero (Catalan Institut of Oncology of L’Hospitalet, Spain)
Chapter 11 – Future I. Still Unapproved Drugs (pp. 163-178)
Rosario García Campelo, M.D., Joaquín Mosquera, M.D. and Aurea Molina, M.D. (A Coruña University Hospital, Spain)
Chapter 12 – Future II. Targeted Therapies in Early-Stage Non-Small Cell Lung Cancer (pp. 179-190)
Elsa Dalmau Pórtulas, M.D., Ph.D. and Marta Ferrer Cardona, M.D. (Parc Tauli University Hospital of Sabadell, Spain)
Chapter 13 – Resistance I. Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR-mutant Non-Small Cell Lung Cancer (pp. 191-210)
Jordi Remón, M.D. and Pilar Lianes, M.D., Ph.D. (Hospital of Mataró, Spain)
Chapter 14 – Resistance II. Conventional Salvage Therapies for the Resistance to Anti-Human Epidermal Growth Factor Receptor Treatments (pp. 211-234)
Diego Márquez-Medina, M.D., Ph.D. (Arnau de Vilanova University Hospital of Lleida, Spain)
Chapter 15 – Other Malignancies I. Breast Cancer (pp. 235-252)
E. Aguirre, M.D., S. Morales M.D. and A. Llombart, M.D., Ph.D. (Arnau de Vilanova University Hospital of Lleida, Spain)
Chapter 16 – Other Malignancies II. Gynaecological and Head and Neck Cancer (pp. 253-274)
Yolanda García García, M.D., Estefania García Pérez, M.D. and Julio Ocaña Rojas, M.D. (Parc Taulí University Hospital of Sabadell, Spain)
Chapter 17 – Other Malignancies III. Digestive Tract (pp. 275-286)
Teresa Taberner-Bonastre, M.D. (Instituto Madrileño de Oncología of Madrid Spain)
Self-Correcting Test
Index